Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.China Biopharma has announced that its partner Soonfast Pharmaceuticals has successfully completed trial production of an antiviral product developed to treat infections from human papillomavirus and herpes simplex virus.
Subscribe to our email newsletter
The all-natural medicine has been approved in China for external use to treat human papillomavirus and herpes simplex virus. Tests have shown an inhibitory effect on the growth of HPV and HSV, and the drug can reduce the infection from HPV and HSV by up to 90% in only two to three days, according to China Biopharma.
According to the agreement reached with Soonfast earlier this year, China Biopharma has the right to distribute the medicine in overseas markets.
China Biopharma plans to launch the drug in overseas markets including Europe and the US. The company and Soonfast also plan to jointly conduct studies on its extracts in both China and US so as to obtain the necessary approval for selling this medicine as an over-the-counter drug.